S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
Bank Accounts: Frozen! (Ad)
Dividends, Short-Term Pain, but Long-Term Gain?
Can Carnival Cruise Lines Set Sail For New Highs? 
Bank Accounts: Frozen! (Ad)
BioNTech Is Ripe For A Rebound In 2023 
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
Bank Accounts: Frozen! (Ad)
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
Is Block a Ticking Time Bomb or a Bargain Bestowed by Hindenburg?
S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
Bank Accounts: Frozen! (Ad)
Dividends, Short-Term Pain, but Long-Term Gain?
Can Carnival Cruise Lines Set Sail For New Highs? 
Bank Accounts: Frozen! (Ad)
BioNTech Is Ripe For A Rebound In 2023 
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
Bank Accounts: Frozen! (Ad)
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
Is Block a Ticking Time Bomb or a Bargain Bestowed by Hindenburg?
S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
Bank Accounts: Frozen! (Ad)
Dividends, Short-Term Pain, but Long-Term Gain?
Can Carnival Cruise Lines Set Sail For New Highs? 
Bank Accounts: Frozen! (Ad)
BioNTech Is Ripe For A Rebound In 2023 
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
Bank Accounts: Frozen! (Ad)
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
Is Block a Ticking Time Bomb or a Bargain Bestowed by Hindenburg?
S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
Bank Accounts: Frozen! (Ad)
Dividends, Short-Term Pain, but Long-Term Gain?
Can Carnival Cruise Lines Set Sail For New Highs? 
Bank Accounts: Frozen! (Ad)
BioNTech Is Ripe For A Rebound In 2023 
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
Bank Accounts: Frozen! (Ad)
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
Is Block a Ticking Time Bomb or a Bargain Bestowed by Hindenburg?
NASDAQ:TCDA

Tricida - TCDA Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range
$0.09
$0.12
50-Day Range
$0.11
$0.19
52-Week Range
$0.09
$13.85
Volume
31.13 million shs
Average Volume
17.62 million shs
Market Capitalization
$6.01 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.00

Tricida MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
15,640.7% Upside
$17.00 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-0.90
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.04) to ($1.15) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.84 out of 5 stars


TCDA stock logo

About Tricida (NASDAQ:TCDA) Stock

Tricida, Inc. is a pharmaceutical company. It focuses on the development and commercialization of its product, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease. The company was founded by Gerrit Klaerner and Craig Jon Hawker on May 22, 2013 and is headquartered in South San Francisco, CA.

Receive TCDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tricida and its competitors with MarketBeat's FREE daily newsletter.

TCDA Stock News Headlines

Firm Retention Summary: Tricida Inc.
"Prepare for Five Years of Famine"
Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast
Tricida Announces Third Quarter 2022 Financial Results
Tricida Provides Strategic Update
Why Tricida Stock Is Tanking Today
"Prepare for Five Years of Famine"
Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast
Why Is Tricida (TCDA) Stock Down 90% Today?
Tricida announces $125M debt facility - Seeking Alpha
Tricida Whale Trades Spotted
6TCDA : Tricida Whale Trades Spotted
See More Headlines
Receive TCDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tricida and its competitors with MarketBeat's FREE daily newsletter.

TCDA Company Calendar

Last Earnings
11/08/2021
Today
3/28/2023
Next Earnings (Estimated)
4/04/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TCDA
Fax
N/A
Employees
57
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$17.00
High Stock Price Forecast
$18.00
Low Stock Price Forecast
$16.00
Forecasted Upside/Downside
+15,640.7%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
5 Analysts

Profitability

Net Income
$-176,570,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
35,851,000
Market Cap
$6.01 million
Optionable
Not Optionable
Beta
0.22

Key Executives

  • Gerrit KlaernerGerrit Klaerner
    President, Chief Executive Officer & Director
  • Geoffrey M. Parker
    Chief Operating & Financial Officer, Executive VP
  • Dawn Parsell
    Executive Vice President-Clinical Development
  • Robert McKague
    Chief Compliance Officer, EVP & General Counsel
  • Annie Yoshiyama
    Chief Accounting Officer & Vice President-Finance













TCDA Stock - Frequently Asked Questions

Should I buy or sell Tricida stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Tricida in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" TCDA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TCDA, but not buy additional shares or sell existing shares.
View TCDA analyst ratings
or view top-rated stocks.

What is Tricida's stock price forecast for 2023?

5 analysts have issued 1-year target prices for Tricida's shares. Their TCDA share price forecasts range from $16.00 to $18.00. On average, they expect the company's share price to reach $17.00 in the next year. This suggests a possible upside of 15,640.7% from the stock's current price.
View analysts price targets for TCDA
or view top-rated stocks among Wall Street analysts.

When is Tricida's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 4th 2023.
View our TCDA earnings forecast
.

How were Tricida's earnings last quarter?

Tricida, Inc. (NASDAQ:TCDA) announced its quarterly earnings data on Monday, November, 8th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by $0.09. During the same quarter last year, the firm posted ($1.55) EPS.

What is Gerrit Klaerner's approval rating as Tricida's CEO?

2 employees have rated Tricida Chief Executive Officer Gerrit Klaerner on Glassdoor.com. Gerrit Klaerner has an approval rating of 100% among the company's employees. This puts Gerrit Klaerner in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Tricida own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tricida investors own include Pfizer (PFE), Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Atara Biotherapeutics (ATRA), bluebird bio (BLUE), Moderna (MRNA) and AT&T (T).

When did Tricida IPO?

(TCDA) raised $175 million in an IPO on Thursday, June 28th 2018. The company issued 10,300,000 shares at $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan and Cowen acted as the underwriters for the IPO.

What is Tricida's stock symbol?

Tricida trades on the NASDAQ under the ticker symbol "TCDA."

Who are Tricida's major shareholders?

Tricida's stock is owned by a number of retail and institutional investors. Top institutional investors include Millennium Management LLC (1.92%), Two Sigma Investments LP (1.90%), Morgan Stanley (0.72%), HRT Financial LP (0.52%), UBS Group AG (0.49%) and Renaissance Technologies LLC (0.43%). Insiders that own company stock include Brian M Isern, Dawn Parsell Otto, Geoffrey M Parker, Gerrit Klaerner, Kurtis R Kurimsky, Orbimed Advisors Llc, Robert J Alpern, Robert Mckague, Sandra I Coufal and Venrock Healthcare Capital Par.
View institutional ownership trends
.

What is Tricida's stock price today?

One share of TCDA stock can currently be purchased for approximately $0.11.

How much money does Tricida make?

Tricida (NASDAQ:TCDA) has a market capitalization of $6.01 million. The company earns $-176,570,000.00 in net income (profit) each year or ($2.36) on an earnings per share basis.

How can I contact Tricida?

Tricida's mailing address is 7000 SHORELINE COURT SUITE 201, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.tricida.com. The company can be reached via phone at (415) 429-7800 or via email at ir@tricida.com.

This page (NASDAQ:TCDA) was last updated on 3/28/2023 by MarketBeat.com Staff